SIM
VYNE icon

Spark Investment Management’s VYNE Therapeutics VYNE Stock Holding History

Spark Investment Management’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-698
Closed -$394K – 712
2019
Q1 		$394K Buy
698
+67
+11% +$32.2K 0.02% 425
2018
Q4 		$187K Buy
+631
New +$283K 0.01% 505

Other funds holding VYNE

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Spark Investment Management's VYNE Position: Q2 2019 in Review

Spark Investment Management sold out of VYNE Therapeutics (VYNE) in Q2 2019, closing a stake of 698 shares — an estimated $394K sold.

Spark Investment Management first reported a position in VYNE in Q4 2018 and held it in 2 quarters. The position peaked at $394K in Q1 2019. 58 funds tracked by Wall St. Rank hold VYNE as of Q2 2019.

  • Spark Investment Management reported no remaining VYNE Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Spark Investment Management sold 698 VYNE Therapeutics shares in Q2 2019, an estimated $394K.
  • Spark Investment Management first reported a position in VYNE Therapeutics in Q4 2018 and held it in 2 quarters.
  • Spark Investment Management's VYNE Therapeutics position peaked at $394K in Q1 2019.
  • 58 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q2 2019.

Based on Spark Investment Management's 13F filing for Q2 2019, filed 12 Aug 2019.